Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: A meta-analysis of randomized controlled trials

Obesity Reviews

Volumn 11, Issue 2, 2010, Pages 150-158

  Czernichow, S ^a,b   Lee, C M Y ^a   Barzi, F ^a   Greenfield, J R ^c   Baur, L A ^a   Chalmers, J ^a   Woodward, M ^a   Huxley, R R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITÉ PARIS 13   (France)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Meta analysis; Obesity; Orlistat; Sibutramine; Trials

Indexed keywords

PLACEBO; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADOLESCENCE; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MEDLINE; META ANALYSIS; OBESITY; QUANTITATIVE ANALYSIS; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADOLESCENT; ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; CYCLOBUTANES; HUMANS; LACTONES; LIPIDS; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; WEIGHT LOSS;

EID: 75149126784     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2009.00620.x     Document Type: Article

References (22)

1. Lobstein T, Baur L, Uauy R. Obesity in children and young people: a crisis in public health. Obes Rev 2004 5 (Suppl. 1 4 104.
2. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. Int J Pediatr Obes 2006 1: 11 25.
3. Whitaker RC, Wright JA, Pepe MS, Seidel KD, Dietz WH. Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med 1997 337: 869 873.
4. Kipping RR, Jago R, Lawlor DA. Obesity in children. Part 1: epidemiology, measurement, risk factors, and screening. BMJ 2008 337: a1824.
5. Oude Luttikhuis H, Baur L, Jansen H, Shrewsbury V, O'Malley C, Stolk PP, Summerbell CD. Interventions for treating obesity in children. Database Syst Rev 2009 1 CD001872.
6. Shield JP, Crowne E, Morgan J. Is there a place for bariatric surgery in treating childhood obesity? Arch Dis Child 2008 93: 369 372.
7. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long-term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007 335: 1194 1199.
8. Lloret-Linares C, Greenfield JR, Czernichow S. Effect of weight-reducing agents on glycaemic parameters and progression to Type 2 diabetes: a review. Diabet Med 2008 25: 1142 1150.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003 327: 557 560.
10. Violante-Ortiz R, Del-Rio-Navarro BE, Lara-Esqueda A, Perez P, Fanghanel G, Madero A, Berber A. Use of sibutramine in obese Hispanic adolescents. Adv Ther 2005 22: 642 649.
11. Reisler G, Tauber T, Afriat R, Bortnik O, Goldman M. Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity. Isr Med Assoc J 2006 8: 30 32.
12. McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Frazer TE, Van HS, Yanovski JA. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab 2004 17: 307 319.
13. Berkowitz RI, Fujioka K, Daniels SR, Hoppin AG, Owen S, Perry AC, Sothern MS, Renz CL, Pirner MA, Walch JK, Jasinsky O, Hewkin AC, Blakesley VA. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 2006 145: 81 90.
14. Daniels SR, Long B, Crow S, Styne D, Sothern M, Vargas-Rodriguez I, Harris L, Walch J, Jasinsky O, Cwik K, Hewkin A, Blakesley V. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study. Pediatrics 2007 120: e147 e157.
15. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 2003 289: 1805 1812.
16. Budd GM, Hayman LL, Crump E, Pollydore C, Hawley KD, Cronquist JL, Berkowitz RI. Weight loss in obese African American and Caucasian adolescents: secondary analysis of a randomized clinical trial of behavioral therapy plus sibutramine. J Cardiovasc Nurs 2007 22: 288 296.
17. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005 293: 2873 2883.
18. Garcia-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Rio-Navarro BE, Dorantes-Alvarez LM. Use of sibutramine in obese Mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2006 28: 770 782.
19. Godoy-Matos A, Carraro L, Vieira A, Oliveira J, Guedes EP, Mattos L, Rangel C, Moreira RO, Coutinho W, Appolinario JC. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab 2005 90: 1460 1465.
20. Maahs D, de Serna DG, Kolotkin RL, Ralston S, Sandate J, Qualls C, Schade DS. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract 2006 12: 18 28.
21. Ozkan B, Bereket A, Turan S, Keskin S. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 2004 163: 738 741.
22. Clapham JC, Arch JR, Tadayyon M. Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmacol Ther 2001 89: 81 121.